Professor, Department of Leukemia, Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX
Chief, Section for Myeloproliferative Neoplasms, Leukemia Department, Department of Leukemia,
The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 – Present
Dr. Verstovsek is a global leader in myeloproliferative neoplasms (MPN) and the Founder/Director of the largest MPN Clinical Research Center worldwide.
Dr. Verstovsek’s contributions in MPN have been globally recognized with numerous invitations as expert speaker/educator/Chair at the most significant national and international conferences. He regularly engages at multiple levels with MPN patients’ advocacy groups/societies.
Dr. Verstovsek has achieved international acclaim for his leadership in developing landmark MPN therapeutics.
Dr. Verstovsek led more than 60 early/advanced phase clinical trials of novel MPN drugs, including ruxolitinib, the only FDA-approved medication for myelofibrosis until 2019, and second-line treatment for polycythemia vera.
Data from MD Anderson webpage: https://faculty.mdanderson.org/profiles/srdan_verstovsek.html